Solara Active Pharma Sciences Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n1gmrl5rd7d439l096t1w5rp.pdf

Key Takeaways


Base Business: The Engine That Worked

Sandeep Rao: "No, no, no, Sajal. There's nothing one-off there. And like always, our story continues despite all the headwinds we are facing and the money that we are losing on the ibuprofen business, I think our base business is what's driving the momentum is what's keeping the tailwinds also."

Ibuprofen: The Drag Being Addressed

Sandeep Rao: "I see a commodity business, which requires investment and gives me negative returns. And on the other hand, I see a base business that gives me 54%, 55% gross margins and 23%, 25% EBITDA. My preference, I would like to invest money available on the base business so I can grow that business to something a lot more meaningful than the current base business."

R&D Revival After a Lost Half-Decade

Sarat Kumar: "So R&D is something which we have spent roughly close to INR200 crores in the past 4, 5 years. However, having said that, at the same time, we are also mindful that our R&D engine has not been able to come up with at least one new product filing in the last 4 years as well."

Margins & Operating Leverage

Sarat Kumar: "We have been maintaining that we will be close to in the range of 25% plus, minus here and there. And this is something which we have been demonstrating quite consistently for the past few quarters, and that is something which should hold true for next few quarters as well."

Balance Sheet & Capital Allocation


Growth Strategy: The Three-Pivot Plan

Sandeep Rao: "I think these are going to be the three pivots around which our growth is going to be centered over the next 3 years."

Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen strategic review conclusionBankers to evaluate sale or facility repurposing; decision to be communicatedH1 FY27
Vizag facility road mapClear plan for utilization or repurposingH1 FY27
Debt reductionReduce debt to ~₹503 crores via rights issue second call proceedsEnd-May '26
Debt-free targetZero debt including working capital debtFY29
DMF filing cadence4–5 DMF filings per yearStarting FY27, annually
Steady-state base business EBITDA margin~25% plus/minusNext 2–3 years
No further capital raisingNo equity or debt issuance plannedIndefinite, from current point
CRAMS polymers carve-outOn hold pending ibuprofen decisionUntil H1 FY27

Key Metrics

MetricQ4 FY26
Revenue₹392 cr, +12% QoQ
Gross margin47%, +170 bps QoQ; absolute value ₹184 cr
EBITDA₹61 cr, +65% QoQ
EBITDA margin16%
Base business EBITDA margin26%, with gross margins of 54%
Developed markets share75% of overall sales
Debt reduction in FY26~₹158 cr, ~21% reduction; ₹113 cr from rights issue first call, ₹45 cr from operational cash flows
Projected debt by end-May '26~₹503 cr, driven by second and final call money proceeds
Capacity utilization~70%, with ~30% spare capacity available
Top 15–20 products concentration~75% of total business
CRAMS annual revenue~₹10–12 cr
Polymers market share~50% plus globally
Annual R&D spend~₹25 cr
Vizag mothballed facility fixed cost₹12–15 cr annually
Base business FY26 growth vs FY25~6%